Fig. 2From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesScatter plot of individual patient responses over time in evaluable patients (n = 28, *Expansion GIST patient). [GIST = gastrointestinal stromal tumor; RCC = renal cell carcinoma; NSCLC = non-small cell lung cancer]Back to article page